iCare

What iCare does

iCare (legal entity: Icare Finland Oy) is a Finnish ophthalmic medical device company and wholly-owned subsidiary of Revenio Group Corporation, headquartered in Vantaa, Finland. The company develops and manufactures hardware and software solutions for retinal screening, diagnostics, and monitoring, with its core product being the DRSplus Fundus Imaging System—an FDA 510(k) cleared device commercially available in the United States for diabetic retinopathy screening and cardiovascular disease risk assessment. iCare generates revenue primarily through hardware sales of medical diagnostic devices to healthcare providers and eyecare professionals, supplemented by AI software integration potential via licensing and royalty arrangements. The company serves two principal customer segments: hospitals, ophthalmology practices, and primary care settings that need retinal screening capabilities, and eyecare professionals requiring advanced diagnostic and imaging solutions. iCare sells through direct enterprise field sales channels globally, targeting hospitals, ophthalmology practices, and primary care settings with positioning around the lack of ophthalmologist access in primary care and the efficiency benefits of AI-enabled screening. Following the August 2024 acquisition of Dutch AI specialist Thirona Retina BV and the June 2026 integration of Visionix's ophthalmic portfolio, iCare now offers a comprehensive suite spanning diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions for eyecare professionals worldwide.

Name

iCare

Legal name

Icare Finland Oy

Website

https://icare-world.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

iCare (Icare Finland Oy) is a Finnish ophthalmic medical device subsidiary of Revenio Group that develops the FDA-cleared DRSplus fundus imaging system and AI-enabled retinal screening tools for hospitals, ophthalmology practices, and primary care providers.

Ownership category

akta.pro rank

Product category

Ophthalmic Diagnostic Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

Keywords

• Ophthalmic medical devices
• Retinal imaging systems
• Diabetic retinopathy screening
• AI diagnostic software
• Fundus cameras

Headquarters

HQ city

Vantaa

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Sales: iCare generates revenue through sale of medical diagnostic devices including fundus imaging systems and related ophthalmic equipment to healthcare providers and eyecare professionals
2. AI Software Integration: Revenue potential from AI-powered diagnostic software integrated with medical devices for retinal screening and cardiovascular risk assessment

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

Core offering

iCare develops and manufactures ophthalmic medical devices, most notably the DRSplus Fundus Imaging System, used for retinal screening, diabetic retinopathy detection, and cardiovascular disease risk assessment. The portfolio has expanded through the Visionix merger to include diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions for eyecare professionals and primary care providers.

Product overview

iCare is a subsidiary of Revenio Group Corporation that develops and manufactures ophthalmic medical devices and AI-enabled diagnostic solutions. The company's product portfolio centers on the DRSplus Fundus Imaging System, an FDA 510(k) cleared retinal screening device. Following the acquisition of Thirona Retina (AI for retinal image analysis) and the merger with Visionix's ophthalmic device and imaging portfolios, iCare now offers a comprehensive suite including diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions for eyecare professionals. The company also partners with Mediwhale to integrate its fundus imaging with AI-powered cardiovascular disease risk assessment software.

Differentiator

Problem solved

Functional benefit

Products and services

• DRSplus Fundus Imaging System An FDA 510(k)-cleared TrueColor confocal fundus camera system used by healthcare providers, primary care settings, and ophthalmology practices for retinal screening, diabetic retinopathy detection, and cardiovascular disease risk assessment.
• Visionix Ophthalmic Portfolio A multi-modality ophthalmic product line resulting from the Visionix merger, encompassing diagnostic imaging, optical coherence tomography (OCT), refraction technology, and AI-enabled workflow solutions for eyecare professionals.

Quantifiable outcome

• iCare's DRSplus device is FDA 510(k) cleared and commercially available in the United States
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• VisionixflagshipStrategic or Co-development Partner · 2 June 2026Revenio Group Corporation officially completed the integration of Visionix's ophthalmic medical device and imaging portfolios with iCare, after announcing the acquisition over a month ago. Revenio purchased Visionix's entire capital share from its French parent company, LT International SAS, creating a combined entity offering diagnostics, imaging, refraction, OCT, and AI-enabled workflow solutions for eyecare professionals.
• Mediwhale Inc.coreStrategic or Co-development Partner · 19 February 2026iCare, a subsidiary of Revenio Group, and South Korea-based Mediwhale Inc. agreed to explore a strategic collaboration integrating iCare's DRSplus fundus imaging system with Mediwhale's Dr. Noon CVD AI software to create a retinal imaging-based platform for cardiovascular disease risk assessment. iCare's device is already FDA 510(k) cleared and commercially available in the United States, while Mediwhale is pursuing FDA De Novo authorization with an estimated H1 2026 timeframe. The partnership aims to establish retinal screening as a tool for systemic health management beyond ophthalmology.
• Thirona Retina B.V.coreTechnology or IntegrationIcare Finland Oy acquired Thirona Retina B.V., a Dutch company specializing in artificial intelligence for retinal image analysis. This acquisition enhances iCare's AI capabilities for retinal screening technology.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Eyenuk: Eyenuk is a U.S.-based AI diagnostics company specializing in autonomous diabetic retinopathy screening via fundus imaging — directly competing with iCare's DRSplus + Thirona Retina AI offering in primary care screening workflows.
• Digital Diagnostics: Digital Diagnostics develops IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy — a direct competitor to iCare's AI-enabled DR screening positioning in U.S. primary care.
• AEYE Health: AEYE Health is an AI retinal screening company focused on autonomous DR detection from fundus images — directly comparable to iCare's Thirona Retina-powered AI screening capability.
• Optomed: Optomed is a Finnish-listed handheld fundus camera and AI screening company — directly competing with iCare's DRSplus in primary care DR screening, and a Nordic peer with similar OEM/screening positioning.
• IRIS (Intelligent Retinal Imaging Systems): IRIS provides AI-enabled retinal screening services in U.S. primary care settings — directly competing with iCare's primary-care DR screening go-to-market motion.

Broad incumbents

• Topcon Healthcare: Topcon is a large Japanese ophthalmic device incumbent offering fundus cameras, OCT, and screening software — competing with the iCare/Visionix combined portfolio across eyecare professionals globally.
• Carl Zeiss Meditec: Carl Zeiss Meditec is a global ophthalmic device leader (OCT, fundus, surgical) — a broad incumbent competing with iCare's expanded portfolio post-Visionix integration in eyecare practices and hospitals.
• Heidelberg Engineering: Heidelberg Engineering specializes in retinal imaging (SPECTRALIS OCT, fundus) — a premium-incumbent peer competing with iCare's DRSplus and integrated imaging portfolio.
• Nidek: Nidek is a Japanese ophthalmic device manufacturer with fundus cameras, OCT, and refraction equipment — overlapping with the iCare/Visionix merged portfolio across eyecare professionals.

Emerging players

• Mediwhale: Mediwhale is a South Korean AI health company developing Dr. Noon CVD (retinal imaging-based cardiovascular risk assessment) — both a partner and adjacent competitor in retinal AI, pursuing FDA De Novo authorization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/icare-worldwide

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iCare